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same H1N1 and B viruses were used for neutralizing 
antibody (neut) tests but A/Moscow/10/99 (H3N2) 
(antigenica[[y similar to A/Panama/H3N2 virus) was 
used in influenza A/H3N2 tests. 
Results: See the table. A[[ outpatient clinic NHL 
patients were screened and those who had not 
received chemotherapy in <3 months and rituximab 
in <6 months were considered. Sp[enctomized pa- 
tients and those receiving systemic corticosteroids 
were excluded. There were no serous adverse re- 
actions noted in any of the 27 enrollees during 
a 6-month period following vaccination. Among 
influenza A/H1N1 and A/H3N2, higher doses were 
associated with increased strain-specific protective 
neutralizing antibody titers. Whereas, this benefi- 
cial effect was not seen in patients receiving higher 
doses of influenza B vaccine. 
Vaccine Dose A/H3 a A/H1 a B a 
Riseb/ GMT c Riseb/ GMT c Riseb/ GMT c 
No. (%) No. (%) No. (%) 
Standard 15 0/4 6.6 2/5 3.3 2/5 1.8 
(0) (40) (40) 
rHA0 15 1/5 7.9 0/4 2.8 1/6 2.5 
(20) (0) (17) 
rHA0 45 2/5 7.9 1/4 2.8 0/5 1.4 
(40) (25) (0) 
rHA0 135 3/5 11.5 2/3 4.0 2/4 2.7 
(60) (67) (50) 
aA/H3 = 4.5-7.5; A/H1 = <1-4; B = <1-2[og2. 
bRise: no. of enro[[ees with antibody rise = four-fo[d or greater. 
c Highest GMT ([og2) 4 or 8 weeks post-vaccination. 
Conclusions: These pre[iminary results indicate a 
potential rHA0 dose-escalation benefit for neutral- 
izing antibody response against influenza A virus. 
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Efficacy of High-Dose (100 mg daily) Caspofungin 
(HD-CASP) Combination Antifungal Therapy in 
Cancer Patients with Invasive Fungal Infections 
(IFIs): Case-Controlled Observational Analysis 
During 2002-2004 
A. Safdar*, G. Rodriguez, K.V.I. Ro[ston, 
H.M. Kantarjian, G.R Bodey, R.E. Champlain, 
D. Kontoyiannis, I.I. Raad. M.D. Anderson Cancer 
Center Houston, TX, USA 
Background: Pneumocandins exert concentration- 
dependent antifunga[ effect, therefore we sought 
to evaluate efficacy (complete or partial response, 
C-PR) of HD-CASP therapy in patients with systemic 
mycosis. 
Methods: IRB approval was obtained to review the 
charts of 97 patients with probable and proven 
IFIs. Conventional-dose (CD) CASP was 70mg fol- 
lowed by 50mg daily. Fisher exact or chi-square 
test and student's t-test or Wi[coxon rank sums 
test were used to assess categorical and continuous 
variables, respectively. 
Results: Among evaluated Cases (n = 34) and con- 
trois (n = 63) there were not statistically significant 
differences between the two groups respect to 
the patients characteristics such as age, acute or 
chronic leukemia, BMT, GVHD, relapsed or refrac- 
tory cancer, co morbidities including DM, COPD, 
CAD, CHF, ARF, hepatic dysfunction, APACHE-II 
score, >600 prednisone equivalent dose prior or 
during CASP therapy, neutropenia prior and dur- 
ing therapy, antifunga[ prophylaxis, probable and 
proven IFI and combination antifunga[ therapy. 
Logistic regression multivariate 4-weeks assess- 
ment showed no difference in response in HD- 
and CD-CASP treatment groups, however, 12 weeks 
assessment showed a significantly improved prob- 
ability of favorable treatment response in pa- 
tients who had received HD-CASP (OR 3.066, 95% Cl 
1.092-8.61, P = 0.00335). 
Parameter Cases (%) Controls (%) P value 
Lung IFI 24 (71) 58 (92) 0.005 
Disseminated IFI 10 (29) 5 (8) <0.05 
Non-Aspergi[[us lung IFI 7 (21) 4 (6) <0.05 
Prior antifunga[ therapy 24 (71) 21 (33) 0.0004 
CASP therapy days a 12.5 (74) 29 (138) 0.0024 
C-PR [4-week] 10 (29) 14 (22) 0.1 
C-PR [12-week] 15 (44) 18 (29) 0.1 
aOive as median (range). 
Conclusions: Despite presence of unfavorable pre- 
dictors patients receiving HD-CASP had improved 
probability of infection resolution. 
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Changing Trends of Bacteremia in Patients with 
Cancer: Analysis of 2080 Quantitative Blood 
Cultures During 1998 and 2004 
A. Safdar*, G. Rodriguez, M. Ba[akrishnan, 
J. Tarrand, K.V.I. Ro[ston. M.D. Anderson Cancer 
Center, Houston, TX, USA 
Background: The severity of bacteria[ bloodstream 
infections (BSI) appears to be related to quanti- 
tative bacteria[ levels (organism load), especially 
in neutropenic cancer patients. We sought to de- 
termine the trends in quantitative patterns of BSI 
caused by various bacteria in patients receiving 
care at our comprehensive cancer center. 
Methods: A retrospective analysis of a[[ consec- 
utive blood cultures processed by Dupont Iso- 
lator 10 System during 1998 and during 2004. 
Only one blood culture per patient per organ- 
ism was included. Quantitative bacteremia was 
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graded as foLLows: Low-grade (<10 colony forming 
units/miLLiLiter (CFU/mL) and intermediate-grade 
(11-100 CFU/mL) are grouped in Low-bacteriaL Load; 
moderate-grade (101-500 CFU/mL), and high-grade 
(>500CFU/mL) are considered as high-bacteriaL 
Load. 
Results: During 1998, 73% of 1055 and 2004, 82% 
of 1025 BSI were caused by Gram-positive bacteria 
(GPB) with the most frequent being coaguLase- 
negative staphylococcus (CONS), 33% and 50% and 
Staphylococcus aureus, 9% and 6%, respectively. 
In Gram-negative bacterial (GNB) BSI, Enterobac- 
teriacae were common (73%, and 56%) foLLowed 
by non-fermentative (NF)-GNB (37% and 44%); Es- 
cherichia coli (24% and 24%) and Pseudomonas 
areusinosa (17% and 19%) being the most com- 
mon GNB species isolated during 1998 and 2004, 
respectively. A significant increase in the num- 
ber of Stenotrophomonas maltophilia bloodstream 
infection was noted during 6-year study interval 
(6% in 1998 vs. 16% in 2004; P<0.01). Compared 
with GPB infections a significant proportion of GNB 
bacteremia were high-grade (18% vs. 39% in 1998, 
and 7% vs. 44% in 2004; P < 0.001). In contrast to 
1998, in 2004 the non-Pseudomonas NF-GNB in- 
cluding S. maltophilia and Acinetobacter species 
were significantly associated with high-bacteriaL 
Load compared to P. aerusinosa infection (47% vs. 
23%; P--0.05). SimiLarLy, the high-bacteriaL Load 
associated with S. aureus (50%) and Streptococucs 
species (35%)vs. CoNS (13%; P < 0.0001) during 1998 
was not noted during 2004 (22% S. aureus, 20% 
Streptococcus species vs. 21% CONS; P >0.5). This 
was due to a significant increase in CoNS high- 
bacterial Load BSI in 2004 (21% vs. 13% in 1998; 
P < 0.01). There was also an interval increase in 
Corynebacterium species high-bacteriaL Load in- 
fections in 2004 compare to 1998 (18% vs. 5%; 
P<0.01). 
Conclusions: A high proportion of GNB were as- 
sociated with high-bacteriaL Load BSI compared to 
GPB infections. In 2004, a significant increase in 
the S. maltophilia bacteremia was accompanied by 
a concomitant rise in the high-bacteriaL Load BSI, 
which may pose a serious chaLLenge in successful 
therapy in immunosuppressed cancer patients with 
often difficuLt-to-treat systemic GNB infection. 
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Prospective Evaluation of Galactomannan 
Enzyme Immunoassay (GM-EIA) and 
(1-3) B-D-Glucan (BG) for the Diagnosis of 
Invasive Fungal Infections in Patients with 
Hematological Malignancy 
R. Hachem*, M. Boktour, T. Daugherty, T. Pham- 
WiLLiams, C. Warneke, R. Chemaky, I. Raad. 
M.D. Anderson Cancer Center, Houston, TX, USA 
Background: Invasive fungaL infection (IFI) remains 
a major cause of morbidity and mortality in cancer 
patients. This is due in part to under diagnosis. 
Previous studies have reported GM-EIA and BG may 
be useful diagnostic tools but the sensitivity is vaM- 
able. We studied the performance of both tests. 
Methods: Between October 2002 and March 2005, 
70 patients were prospectively foLLowed for 12 
weeks. A total of 600 samples were tested in 4 
groups of patients: invasive aspersillosis (IA), other 
mold (FusaMum, zygomycosis, etc.), candidemia, 
and control patients (soLid tumors with no radi- 
oLogicaL, microbioLogicaL or cLinicaL evidence of 
IA). BLood samples were obtained twice on week 
one and once every other week for a total of 
12 weeks. CLinicaL characteristics, including an- 
timicrobiaL therapy, were obtained on aLL patients. 
Testing was performed with serial serum samples 
according to the manufacturer's pecifications. An 
index cut-off for positivity was 0.5 for GM-EIA and 
a serum BG Level of 980 pg/mL was chosen. 
Results: Sensitivity (Sens), specificity (Spec), posi- 
tive predictive value (PPV) and negative predictive 
value (NPV) of the two assays performed on 600 
samples are compared in the table. 
IFI Assay Sens Spec PPV NPV 
Aspergi((osis GM- EIA 0.36 1.00 1.00 0.60 
BG 0.68 0.76 0.75 0.70 
Other mo[d GM-EIA 0.08 1.00 1.00 0.66 
BG 0.75 0.76 0.64 0.84 
Candidemia GM-EIA 0.08 0.95 .50 0.65 
BG 0.67 0.76 0.62 0.80 
Conclusion: BG has better sensitivity than GM-EIA 
in the diagnosis of hematologic patients with IA, 
candidemia and other mold infections. GM might 
be more specific for IA. 
